To assess the impact of KRAS mutation on tumor glucose uptake, we examined the expression of GLUT-1 by immunohistochemistry in resected ICC specimens (Fig. 2). This evidence concerns the gene SLC2A1 and intrahepatic cholangiocarcinoma.